A pilot phase II study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma.Lauren Cobb, Amir A. Jazaeri, Joseph Davis et al.|Journal of Clinical Oncology|2022Cited by 34
Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survivalDavid M. Gershenson, Charlotte C. Sun, Shannon N. Westin et al.|Gynecologic Oncology|2022Cited by 16
Clinical and Genomic Landscape of RAS Mutations in Gynecologic CancersJi Son, David S. Hong, Yingao Zhang et al.|Clinical Cancer Research|2024Cited by 13
Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancerNicole D. Fleming, Anil K. Sood, Shannon N. Westin et al.|International Journal of Gynecological Cancer|2020Cited by 8
ENPAC: phase II trial with safety lead of enzalutamide in combination with paclitaxel and carboplatin for advanced or recurrent endometrioid endometrial adenocarcinomaShannon N. Westin, Robert L. Coleman, Bryan Fellman et al.|Gynecologic Oncology|2021Cited by 6